FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | IN BENEFICIAL | <b>OWNERSHIP</b> |
|-----------|------------|---------------|------------------|

| OMB APPROVAL       |           |  |  |  |  |  |  |  |  |
|--------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:        | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average  | ourden    |  |  |  |  |  |  |  |  |
| hours per response | 0.5       |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Crowley John F   |   |  |        |                   |                              | 2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [ FOLD ] |                  |  |  |               |   |  |   | (Check all application X Director |   | or 10% Owner  |                |  |  |  |
|--|---|--|--------|-------------------|------------------------------|--|------------------|--|--|---------------|---|--|---|-----------------------------------|---|---|----------------|--|--|--|
| (Last) (First) (Middle) C/O AMICUS THERAPEUTICS, INC. 3675 MARKET STREET   |   |  |        |                   |                              | 3. Date of Earliest Transaction (Month/Day/Year) 11/01/2021                    |                  |  |  |               |   |  |   |                                   | X Officer (give title Other (specify below)  Chairman & CEO |   |                |  |  |  |
| (Street) PHILADELPHIA PA 19104 (City) (State) (Zip)  |   |  |        |                   | -   4. I<br>-                | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. I                  |                  |  |  |               |   |  |   |                                   |   | lividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person |                |  |  |  |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |   |  |        |                   |                              |  |                  |  |  |               |   |  |   |                                   |   |   |                |  |  |  |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye   |   |  |        | Execution Date,   |                              | 3.<br>Transaction<br>Code (Instr.<br>8)  |                  | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 an |  | d 5)          | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following |  | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) |                                   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership         |   |                |  |  |  |
|  |   |  |        |                   |                              |  | Code             | v  | Amount                                       | (A) or<br>(D) | Price   |  | Reported<br>Transact<br>(Instr. 3                                 | tion(s)                           |   |   | (Instr. 4)     |  |  |  |
| Common Stock 11/01/2   |   |  |        | 2021              | 21                           |  |                  | S <sup>(1)</sup>   |  | 7,819         | D   | \$10.8   | 3007 <sup>(2)</sup>   | 824                               | 1,526   | 5 D   |                |  |  |  |
| Common Stock 11/03/202   |   |  |        | 021               | 21                           |  | M                |  | 27,739                                       | A             | \$3   | .82  | 852   | 2,265                             |   | D   |                |  |  |  |
| Common Stock 11/03/202   |   |  |        | 021               | 21                           |  | S <sup>(1)</sup> |  | 27,739                                       | D             | \$  | 12   | 824   | 24,526                            |   | D   |                |  |  |  |
| Common Stock   |   |  |        |                   |                              |  |                  |  |  |               |   | 64,895 I By Trust  |   |                                   |   |   |                |  |  |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |  |        |                   |                              |  |                  |  |  |               |   |  |   |                                   |   |   |                |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | if any | emed<br>ion Date, | 4.<br>Transa<br>Code (<br>8) | ction  | 5. Number of     |  | 6. Date Exerc<br>Expiration D<br>(Month/Day/ |               | cisable and<br>late   | 7. Title and Amor<br>of Securities<br>Underlying<br>Derivative Secur<br>(Instr. 3 and 4) |   | ount 8.<br>D<br>So<br>rity (In    | Price of<br>erivative<br>ecurity<br>1str. 5)                | 9. Number<br>derivative<br>Securities<br>Beneficial<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4)                   | e (Ces Fally C | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |   |  |        |                   | Code                         | v  | (A)              | (D)  | Date<br>Exerc                                | isable        | Expiration<br>Date  | Title  | or<br>Num<br>of<br>Shai   | .                                 |   |   |                |  |  |  |
| Stock<br>Options<br>(right to<br>buy)  | \$3.82  | 11/03/2021                                 |        |                   | М                            |  |                  | 27,739   |  | (3)           | 06/24/2024  | Commo  | 27,   | 739                               | \$0.00  | 0   |                | D  |  |  |

## Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$10.45 to \$10.94 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. All of these options were fully vested and exercisable as of the transaction date.

## Remarks:

/s/ Christian Formica, Attorney-11/03/2021 in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.